Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NUVL files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNuvalent submits NDA for neladalkib in ALK+ lung cancer, reports Q1 loss of $109.3M
Filed May 7, 2026 · Period ending May 7, 2026 · ~1 min read
Key Changes
-
high
Submitted New Drug Application to FDA for neladalkib in ALK-positive non-small cell lung cancer patients previously treated with tyrosine kinase inhibitors, based on ALKOVE-1 Phase 1/2 trial data showing encouraging activity and intracranial responses.
Exhibit 99.1 view on EDGAR → -
high
Reported Q1 2026 net loss of $109.3M with R&D expenses of $83.6M and G&A expenses of $35.8M. Cash position of $1.3B expected to fund operations into 2029.
Exhibit 99.1 view on EDGAR → -
medium
Plans to submit data to FDA in second half of 2026 to support label expansion of zidesamtinib for treatment-naïve ROS1-positive NSCLC patients, broadening potential patient population.
Exhibit 99.1 view on EDGAR → -
medium
Presented ARROS-1 trial data showing zidesamtinib demonstrated activity in heavily pre-treated ROS1-positive NSCLC patients, including those with ROS1 G2032R resistance mutation and intracranial complete responses.
Exhibit 99.1 view on EDGAR → -
low
Promoted Benjamin Lane to Chief Technology Operations Officer and Kirsten Duncan to Vice President, Medical Affairs as company prepares for potential commercial launches.
Exhibit 99.1 view on EDGAR →
Summary
Nuvalent reached a significant regulatory milestone by submitting its first New Drug Application to the FDA for neladalkib, targeting ALK-positive non-small cell lung cancer patients who have already received tyrosine kinase inhibitor treatment. The submission is based on Phase 1/2 ALKOVE-1 trial data demonstrating encouraging overall activity, intracranial responses, and a generally well-tolerated safety profile. This marks the company's transition from pure clinical-stage to a potential commercial-stage biotech.
The company reported a Q1 2026 net loss of $109.3 million, reflecting elevated R&D spending of $83.6 million as it advances multiple clinical programs. With $1.3 billion in cash and marketable securities, management projects runway into 2029, providing sufficient capital to support the neladalkib NDA review process and continued development of zidesamtinib. The company also presented encouraging ARROS-1 data for zidesamtinib in heavily pre-treated ROS1-positive patients and plans a label expansion submission in the second half of 2026 for treatment-naïve patients, which could significantly expand the addressable market if approved.
Section-by-Section Diff
Event · Exhibit 99.1
Nuvalent submitted NDA for neladalkib in ALK+ NSCLC, reported Q1 2026 loss of $109.3M, and promoted two executives.
Added in current filing · view on EDGAR →
Clinical data from a subgroup of patients with advanced ROS1-positive NSCLC in the ARROS-1 clinical trial who had been previously treated with the dual TRK/ROS1 TKIs
repotrectinib and/or taletrectinib. Treatment with zidesamtinib resulted in clinically meaningful activity in this heavily pre-treated subgroup, including activity in tumors with the ROS1 G2032R resistance mutation and intracranial complete responses for patients with CNS disease.
Nuvalent presented new clinical data at the AACR Annual Meeting 2026 showing that zidesamtinib demonstrated clinically meaningful activity in heavily pre-treated ROS1-positive NSCLC patients who had previously received dual TRK/ROS1 inhibitors. The data included activity against the ROS1 G2032R resistance mutation and intracranial complete responses in patients with CNS disease.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 23, 2026 · How we verify